Radiofrequency Ablation Device Market Global Forecast Report by Product (Capital Equipment, Disposable Equipment, Reusable Equipment) Application (Oncology, Cardiology, Cosmetic Surgery, Gynecology, Others) End Users (Hospitals, Ambulatory Services, Others) Countries and Company Analysis, 2024-2032
Buy NowRadiofrequency Ablation Device Market Analysis
The Global Radiofrequency Ablation Device Market size will surpass US$ 9,981.0 Million by 2032 from US$ 4,061.0 Million in 2023, with a CAGR of 10.51% from 2024 to 2032.
Radiofrequency Ablation Device Market Outlook
Radiofrequency ablation is a medical technique where a tumor, other diseased tissue, or a piece of the heart's electrical conduction system is ablated using heat produced by medium-frequency alternating current (350–500 kHz). RFA is usually performed as an outpatient operation under conscious sedation or local anesthetics.
It is known as radiofrequency catheter ablation when it is given via a catheter. Compared to low-frequency AC or DC pulses that have been used in the past, radiofrequency current has two major advantages: it is very specific in treating the desired tissue without causing a lot of collateral damage, and it does not directly stimulate nerves or heart muscle, so it can often be used without general anaesthesia.
| Report Features | Details |
|
Base Year |
2023 |
|
Forecast Years |
2024 - 2032 |
|
Historical Years |
2019 - 2023 |
|
Market Size in 2023 |
US$ 4,061.0 Million |
|
Market Forecast in 2032 |
US$ 9,981.0 Million |
|
Market Growth Rate (2024-2032) |
10.51% |
Growing cancer prevalence:
Growing cancer prevalence: Over the course of the forecast period, rising cancer prevalence is anticipated to fuel the expansion of the worldwide market for radiofrequency ablation devices used in pain management. For example, the World Health Organization reported in February 2022 that cancer is the primary cause of mortality globally, accounting for around 10 million fatalities in 2020, or roughly one in six deaths. The most prevalent malignancies are those of the breast, lungs, colon, rectum, and prostate. According to new instances, breast cancer accounted for 2.26 million cases in 2020, making it the most common disease. 2.21 million instances of lung cancer. 1.93 million instances involving the colon and rectum. 1.41 million instances of prostate.
Growing older population:
Over the course of the forecast period, the global market for radiofrequency ablation devices for pain management is anticipated to rise as a result of an aging population. For example, in October 2022, the World Health Organization reported that in 2020, there were more adults 60 years of age and older than children under the age of five. The percentage of people over 60 in the world will almost treble from 12% to 22% between 2015 and 2050. The number of people 60 and older will make up 1.4 million of the population by 2020, up from one million in 2020. The number of persons in the globe who are 60 years of age or older is predicted to double (to 2.1 million) by 2050. It is anticipated that between 2020 and 2050, the number of people 80 years of age or older will treble, reaching 426 million.
North America Radiofrequency Ablation Device Market
The rising incidence of chronic illnesses, the growing need for minimally invasive operations, the growing number of product launches, and the growing strategic initiatives by major industry players are the main drivers propelling the expansion of the radiofrequency (RF) ablation devices market in North America. Over the course of the forecast period, the United States is anticipated to hold a sizable proportion of the researched market in the North American region. For example, the 2022 American Cancer Society, Inc. projects that there will be roughly 236,740 new cases of lung cancer identified in the nation in 2022. The same source predicted that kidney cancer will claim 13,920 lives and 79,000 new cases by 2022. Therefore, it is anticipated that the rising incidence of cancer will increase demand for ablation devices, propelling the market's expansion.
Furthermore, the main market participants' strategic endeavors—such as new program releases, collaborations, mergers, and acquisitions—are probably going to propel the market's expansion. To treat patients with recurrent atrial fibrillation that has not responded to medication therapy, the Food and Drug Administration, for example, approved Medtronic's DiamondTemp irrigated ablation catheter in the RF cardiac ablation area in February 2021.
Global Radiofrequency Ablation Device Company Analysis:
Some leading Radiofrequency Ablation Device companies are Boston Scientific Corporation, Inc., Abbott Laboratories, AtriCure, Inc., Medtronic plc, Stryker, Smith & Nephew plc, Conmed Corporation, Hologic, Inc.
Global Radiofrequency Ablation Device Company News:
May 2024: Five Innovative Medical Technologies That Will Revolutionize Patient Care in 2024 Have Been Identified by Clarivate.
May 2024: Atrial fibrillation clinical trials can now employ the Apple Watch. The FDA certified the Apple Watch's atrial fibrillation history function for clinical trials under the medical device development tools (MDDT) program, setting a precedent for the industry and making it the first digital health device to receive this certification.
November 2023: The new Symplicity System from Medtronic, a radiofrequency ablation tool for atrial fibrillation treatment, has been released (AFib). The Symplicity System is intended to give medical professionals a secure and efficient method of treating patients with AFib.A new radiofrequency ablation tool for the management of cardiac arrhythmias, the CoolTouch XP Ablation Catheter, has been introduced by Boston Scientific. The CoolTouch XP Ablation Catheter is intended to give medical professionals a more accurate and regulated method of ablation of heart tissue.Ventricular tachycardia (VT) can now be treated with Abbott Laboratories' new radiofrequency ablation device, the Navistar Ablation System. The goal of the Navistar Ablation System is to give doctors a more efficient way to treat patients with VT.
September 2023: Google Cloud and KARL STORZ GmbH & Co. KG have announced a collaboration to create innovative AI-driven radiofrequency ablation solutions. Through this agreement, new solutions that can enhance patient care and results will be developed by combining the AI capabilities of Google Cloud with the radiofrequency ablation device experience of KARL STORZ.The unveiling of Smith & Nephew plc's new NAVISENT ENT navigation system has been announced. With the NAVISENT system, radiofrequency ablation treatments can be performed with real-time 3D imaging of the patient's anatomy by the surgeon.
Product – Market Breakup in 3 Viewpoints
- Capital Equipment
- Disposable Equipment
- Reusable Equipment
Application – Market Breakup in 5 Viewpoints
- Oncology
- Cardiology
- Cosmetic Surgery
- Gynecology
- Others
End Users – Market Breakup in 3 Viewpoints
- Hospitals
- Ambulatory Services
- Others
Geography – Market Breakup of 18 countries
North America
• United States
• Canada
Europe
• France
• Germany
• Italy
• Spain
• United Kingdom
• Netherlands
Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
Latin America
• Brazil
• Mexico
Middle East & Africa
• South Africa
• UAE
Rest of the World
Company Insights:
• Overview
• Recent Development
• Product Portfolio
• Revenue
Key Players Analysis:
- Boston Scientific Corporation, Inc.
- Abbott Laboratories
- AtriCure, Inc.
- Medtronic plc
- Stryker
- Smith & Nephew plc
- Conmed Corporation
- Hologic, Inc.
Report Details:
| Report Features | Details |
| Base Year |
2023 |
| Historical Period |
2019 - 2023 |
| Forecast Period |
2024 - 2032 |
| Market |
US$ Million |
| Segment Covered |
Product, Application, End User and Countries |
| Countries Covered |
|
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Key Questions Answered in This Report:
• How big is the Radiofrequency Ablation Device market?
• What is the Radiofrequency Ablation Device market growth rate?
• Who are the key players in Radiofrequency Ablation Device market?
• What are the factors driving the Radiofrequency Ablation Device market?
• Which Region held the largest market share in the Radiofrequency Ablation Device market?
Customization Services available
• Analysis of Market Size and Its Segments
• More Company Profiles (Upto 10 without any additional cost):
• Additional Countries (Other than mentioned Countries):
• Region/Country Specific Reports:
• Market Entry Strategy:
• Region-Specific Market Dynamics:
• Regional Market Share Analysis:
• Trade Analysis:
• Production Insights:
• Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
• Talk to our analysts to get more precious information on the current market trends.
• Include more countries and segments and customize the report based on the final requirement.
• Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
• Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities
5. SWOT Analysis
6. Global Radiofrequency Ablation Devices Market
7. Global Radiofrequency Ablation Devices– Market Share Analysis
7.1 By Product
7.2 By Application
7.3 By End User
7.4 By Country
8. Product
8.1 Capital Equipment
8.2 Disposable Equipment
8.3 Reusable Equipment
9. Application
9.1 Oncology
9.2 Cardiology
9.3 Cosmetic Surgery
9.4 Gynecology
9.5 Others
10. End User
10.1 Hospital
10.2 Ambulatory Surgical Centers
10.3 Others
11. Country
11.1 North America
11.1.1 United States
11.1.2 Canada
11.2 Europe
11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Netherlands
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.4 Latin America
11.4.1 Brazil
11.4.2 Mexico
11.5 Middle East & Africa
11.5.1 South Africa
11.5.2 UAE
11.6 Rest of the World
12. Key Players
12.1 Boston Scientific Corporation, Inc.
12.1.1 Overview
12.1.2 Recent Development
12.1.3 Product Portfolio
12.1.4 Revenue
12.2 Abbott Laboratories
12.2.1 Overview
12.2.2 Recent Development
12.2.3 Product Portfolio
12.2.4 Revenue
12.3 AtriCure, Inc.
12.3.1 Overview
12.3.2 Recent Development
12.3.3 Product Portfolio
12.3.4 Revenue
12.4 Medtronic plc
12.4.1 Overview
12.4.2 Recent Development
12.4.3 Product Portfolio
12.4.4 Revenue
12.5 Stryker
12.5.1 Overview
12.5.2 Recent Development
12.5.3 Product Portfolio
12.5.4 Revenue
12.6 Smith & Nephew plc
12.6.1 Overview
12.6.2 Recent Development
12.6.3 Product Portfolio
12.6.4 Revenue
12.7 Conmed Corporation
12.7.1 Overview
12.7.2 Recent Development
12.7.3 Product Portfolio
12.7.4 Revenue
12.8 Hologic, Inc.
12.8.1 Overview
12.8.2 Recent Development
12.8.3 Product Portfolio
12.8.4 Revenue
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com